muraglitazar has been researched along with glycine in 65 studies
| Studies (muraglitazar) | Trials (muraglitazar) | Recent Studies (post-2010) (muraglitazar) | Studies (glycine) | Trials (glycine) | Recent Studies (post-2010) (glycine) |
|---|---|---|---|---|---|
| 85 | 10 | 25 | 35,163 | 756 | 8,415 |
| Protein | Taxonomy | muraglitazar (IC50) | glycine (IC50) |
|---|---|---|---|
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | 1.4852 | |
| Sodium- and chloride-dependent glycine transporter 1 | Homo sapiens (human) | 106 | |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | 0.3253 | |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 0.3253 | |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | 0.3253 | |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | 0.3253 | |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | 0.3253 | |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | 0.3253 | |
| Sodium- and chloride-dependent glycine transporter 2 | Homo sapiens (human) | 128 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 52 (80.00) | 29.6817 |
| 2010's | 11 (16.92) | 24.3611 |
| 2020's | 2 (3.08) | 2.80 |
| Authors | Studies |
|---|---|
| Biller, SA; Cap, M; Chandrasena, G; Chang, SY; Chen, S; Cheng, L; Cheng, PT; Devasthale, PV; Doweyko, A; Farrelly, D; Golla, R; Grover, G; Hariharan, N; Harrity, T; Humphreys, WG; Jeon, Y; Ma, Z; Moore, L; Qu, F; Ren, J; Ryono, DE; Sasseville, VG; Seethala, R; Selan, F; Shao, C; Sleph, P; Sun, W; Tieman, A; Wang, W; Wetterau, JR; Zhang, H | 1 |
| Barlocco, D | 1 |
| Erlich, R | 1 |
| Buse, JB; Davidson, JA; Frederich, R; Lin, KC; Montoro, R; Rubin, CJ; Shockey, G; Viraswami-Appanna, K | 1 |
| Nissen, SE; Topol, EJ; Wolski, K | 1 |
| Brophy, JM | 1 |
| Aranibar, N; Bonacorsi, S; Cheng, PT; Hanson, R; Huang, Y; Humphreys, WG; Swaminathan, A; Wu, S; Zhang, D; Zhang, H; Zhu, M | 1 |
| Kordella, T | 1 |
| Doux, JD; Lee, PY; Yun, AJ | 1 |
| Cox, SL | 1 |
| Biller, S; Cap, M; Chen, S; Cheng, PT; Chu, C; Devasthale, P; Farrelly, D; Fenderson, W; Gregg, R; Gu, L; Hariharan, N; Harrity, T; Jeon, Y; Kunselman, L; Mookhtiar, KA; Ponticiello, R; Qu, F; Ren, J; Ryono, D; Seethala, R; Shao, C; Tieman, A; Wang, W; Wetterau, J; Yang, WP; Zhang, H; Zhou, M | 1 |
| Aurang, C; Cheng, PT; Everett, DW; Humphreys, WG; Mosqueda-Garcia, R; Swaminathan, A; Wang, L; Wu, S; Xue, Y; Zhang, D | 1 |
| Liu, J; Pursley, J; Unger, S; Xue, YJ | 1 |
| Cheng, PT; Everett, DW; Humphreys, WG; Li, W; Wang, L; Zhang, D; Zhang, H | 1 |
| Lebovitz, H | 1 |
| Srinivas, N; Yao, M | 1 |
| Liu, J; Unger, S; Xue, YJ | 1 |
| Finkelstein, JB | 1 |
| Heinzl, S | 1 |
| Liebson, PR | 1 |
| Belder, R; DeFronzo, RA; Fiedorek, FT; Gross, J; Kendall, DM; Ledeine, JM; Mohideen, P; Norwood, P; O'Mahony, M; Roberts, A; Rubin, CJ; Sall, K; Sloan, G | 1 |
| Beckey, C; Parra, D; Thomas, T | 1 |
| Najman, DM | 1 |
| Doggrell, SA | 1 |
| Ceska, R; Stulc, T | 1 |
| Fiévet, C; Fruchart, JC; Staels, B | 1 |
| Bonacorsi, S; Chandrasena, G; Cheng, PT; Hariharan, N; Hosagrahara, V; Humphreys, WG; Li, W; Mitroka, J; Raghavan, N; Shyu, WC; Wang, L; Yao, M; Yeola, S; Zhang, D; Zhang, H; Zhang, L; Zhu, M | 1 |
| Chandrasena, G; Davis, CD; Humphreys, WG; Ma, L; Wang, L; Zhang, D; Zhang, H; Zhu, M | 1 |
| Srinivas, N; Swaminathan, A; Yao, M | 1 |
| Arnold, LL; Cano, M; Cohen, SM; Dominick, MA; Mitroka, J; Sanderson, TP; Schilling, BE; Van Vleet, TR; Waites, CR; White, MR | 1 |
| Chandrasena, G; Chang, SY; Cheng, PT; Hariharan, N; Hosagrahara, VP; Humphreys, WG; Koplowitz, B | 1 |
| Arnold, LE; Cano, M; Cohen, SM; Dominick, MA; Moehlenkamp, JD; Sanderson, TP; Schilling, BE; Tannehill-Gregg, S; Van Vleet, T; Waites, CR; White, MR | 1 |
| Bansal, VS; Bora, RS; Gupta, A; Khanna, V; Khattar, SK; Mittra, S; Priyadarsiny, P; Roy, S; Saini, KS; Sangle, G; Sattigeri, J; Sharma, L; Sharma, S; Tandon, R | 1 |
| Belder, R; Chen, S; Cheng, PT; Devasthale, P; Egan, D; Farrelly, D; French, M; Gu, L; Hariharan, N; Harrity, T; Janovitz, E; Kunselman, L; Peters, A; Ponticiello, R; Staal, A; Swartz, J; Taylor, S; Tozzo, E; Welzel, G; Whaley, J; Zebo, R | 1 |
| Arnold, LL; Cohen, SM; Dominick, MA; Minnema, D; Sanderson, TP; Schilling, BE; Tannehill-Gregg, SH; Ulland, B; Voelker, R; Waites, CR | 1 |
| Kim, JK; Kim, MK; Kim, NJ; Koo, BW; Lee, KO; Li, F; Lim, JI; Min, KH; Park, HJ; Suh, YG; Yoo, JK | 1 |
| Dominick, MA; Sanderson, TP; Schilling, BE; Waites, CR | 1 |
| Miller, JW; Ohmer, J; Sasich, LD | 1 |
| Akinsanya, JB; Raghavan, N; Xue, YJ; Zhang, D | 1 |
| Moseley, RH | 1 |
| Fiedorek, FT; Ledeine, JM; Rubin, CJ | 1 |
| Achanzar, W; Cheng, P; Cosma, G; Delmonte, T; Dracopoli, NC; Geese, WJ; Hariharan, N; Hui, L; Krishnan, B; Ordway, N; Ranade, K; Rubin, C; Tomlinson, L | 1 |
| Goel, A; Jain, M; Jamili, J; Makadia, P; Patel, M; Patel, P; Patil, P; Pingali, H; Sairam, KV; Shah, S; Zaware, P | 1 |
| Cheng, PT; Zhang, D; Zhang, H | 1 |
| Wang, L; Zhang, D; Zhao, W; Zhu, M | 1 |
| Charbonnel, B | 1 |
| Sasich, LD; Sukkari, SR; Tuttle, DA | 1 |
| De Pril, V; Fiedorek, FT; Rubin, CJ | 1 |
| Fiedorek, FT; Rubin, CJ; Viraswami-Appanna, K | 1 |
| Chen, S; Cheng, PT; Humphreys, WG; Li, W; Obermeier, M; Raghavan, N; Ramanathan, R; Tao, S; Wang, L; Xue, Y; Yang, Z; Zhang, D; Zhang, H | 1 |
| Claude, N; Guillouzo, A; Renaud, MP; Rogue, A; Spire, C | 1 |
| Casolaro, A; Cersosimo, E; DeFronzo, RA; Fernandez, M; Ferrannini, E; Gastaldelli, A; Hardies, J; Musi, N; Petz, R; Tantiwong, P; Triplitt, C | 1 |
| Amacher, DE; Boucher, GG; Francone, O; Kerlin, RL; Morton, D; Pettersen, JC; Pruimboom-Brees, IM; Will, Y | 1 |
| Farkouh, M; Plutzky, J; Rosenson, RS; Wright, RS | 1 |
| Asmawi, MZ; Aulaskari, PH; Kolmonen, A; Leppänen, T; Lindholm, M; Moilanen, E; Paukkeri, EL; Yam, MF | 1 |
| Anthérieu, S; Claude, N; de la Moureyre-Spire, C; Guillouzo, A; Rogue, A; Umbdenstock, T; Vluggens, A; Weaver, RJ | 1 |
| Brito, JP; Gionfriddo, MR; Leppin, AL; Montori, VM; Morey-Vargas, OL; Murad, MH | 1 |
| Hämäläinen, M; Isotalo, T; Kellomäki, M; Kotsar, A; Laurila, M; Salenius, JP; Suominen, V; Tammela, TL; Uurto, I | 1 |
| Cersosimo, E; Coletta, DK; DeFronzo, RA; Fernandez, M; Gastaldelli, A; Musi, N | 1 |
| Amoroso, R; Maccallini, C; Mollica, A | 1 |
| Califf, RM; Demets, D; George, JT; Gerstein, HC; Granger, C; Green, JB; Hobbs, T; Holman, RR; Lawson, FC; Leiter, LA; McGuire, DK; McMurray, J; Pagidipati, NJ; Pfeffer, MA; Reusch, J; Riesmeyer, JS; Roe, MT; Rosenberg, Y; Sharma, A; Temple, R; Wiviott, S | 1 |
| Drosatos, K; Kalliora, C | 1 |
10 review(s) available for muraglitazar and glycine
| Article | Year |
|---|---|
Muraglitazar (Bristol-Myers Squibb/Merck).
Topics: Animals; Drug Industry; Glycine; Humans; Hypoglycemic Agents; Oxazoles; PPAR alpha; PPAR gamma | 2005 |
Muraglitazar: an agent for the treatment of type 2 diabetes and associated dyslipidemia.
Topics: Adult; Aged; Animals; Area Under Curve; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Glycated Hemoglobin; Glycine; Half-Life; Humans; Hypoglycemic Agents; Male; Oxazoles; Peroxisome Proliferator-Activated Receptors; Tissue Distribution | 2005 |
Diabetes: assessing the pipeline.
Topics: Adamantane; Alkanesulfonates; Amyloid; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exenatide; Glycine; Humans; Hypoglycemic Agents; Indoles; Islet Amyloid Polypeptide; Maleimides; Nitriles; Oxazoles; Peptides; Phenylpropionates; Piperidines; PPAR alpha; PPAR gamma; Protein Kinase C; Pyrazoles; Pyrrolidines; Receptor, Cannabinoid, CB1; Receptors, Glucagon; Rimonabant; Venoms; Vildagliptin | 2006 |
[Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists].
Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glycine; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Oxazoles; Peroxisome Proliferator-Activated Receptors; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin | 2006 |
Muraglitazar and the FDA: what constitutes drug safety?
Topics: Animals; Blood Glucose; Databases, Factual; Diabetes Mellitus, Type 2; Drug Approval; Glycine; Humans; Oxazoles; Peroxisome Proliferator-Activated Receptors; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration | 2006 |
PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome.
Topics: Alkanesulfonates; Animals; Diabetes Mellitus, Type 2; Glycine; Humans; Metabolic Syndrome; Models, Biological; Oxazoles; Phenylpropionates; PPAR alpha; PPAR gamma | 2006 |
Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects.
Topics: Alkanesulfonates; Diabetic Angiopathies; Glycine; Humans; Hypoglycemic Agents; Insulin Resistance; Ligands; Oxazines; Oxazoles; Phenylpropionates; Phosphorylation; PPAR alpha; PPAR delta; PPAR gamma; Thiazolidinediones; Thiophenes; United States; United States Food and Drug Administration | 2012 |
Systematic reviews to ascertain the safety of diabetes medications.
Topics: Acidosis, Lactic; Blood Glucose; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Female; Fractures, Bone; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Male; Meta-Analysis as Topic; Metformin; Oxazoles; Pancreatic Neoplasms; Risk Assessment; Rosiglitazone; Thiazolidinediones; Urinary Bladder Neoplasms | 2014 |
The Positive Regulation of eNOS Signaling by PPAR Agonists in Cardiovascular Diseases.
Topics: Animals; Cardiovascular Diseases; Glycine; Humans; Nitric Oxide Synthase Type III; Oxazoles; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2017 |
The Glitazars Paradox: Cardiotoxicity of the Metabolically Beneficial Dual PPARα and PPARγ Activation.
Topics: Alkanesulfonates; Animals; Cardiotoxicity; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Energy Metabolism; Glycine; Humans; Hypoglycemic Agents; Oxazoles; Phenylpropionates; PPAR alpha; PPAR gamma; Risk Assessment; Risk Factors; Signal Transduction; Thiophenes | 2020 |
10 trial(s) available for muraglitazar and glycine
| Article | Year |
|---|---|
Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Insulin; Male; Middle Aged; Oxazoles; Peroxisome Proliferator-Activated Receptors | 2005 |
Structural elucidation of human oxidative metabolites of muraglitazar: use of microbial bioreactors in the biosynthesis of metabolite standards.
Topics: Bioreactors; Biotransformation; Cunninghamella; Feces; Glycine; Humans; Oxazoles; Oxidation-Reduction; PPAR alpha; PPAR gamma; Saccharopolyspora | 2006 |
Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A
Topics: Adult; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycine; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Oxazoles; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Triglycerides | 2006 |
Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling.
Topics: Animals; Bile; Dogs; Feces; Glycine; Hepatocytes; Humans; Macaca fascicularis; Male; Mice; Mice, Inbred Strains; Oxazoles; PPAR alpha; PPAR gamma; Protein Binding; Rats; Rats, Sprague-Dawley | 2007 |
Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active-control trial with glimepiride.
Topics: Administration, Oral; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipids; Male; Metformin; Middle Aged; Oxazoles; Sulfonylurea Compounds; Time Factors; Treatment Outcome | 2008 |
Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor gamma agonists.
Topics: Animals; Diabetes Mellitus, Type 2; Edema; Endothelin-1; Female; Gene Expression Regulation; Glycine; Humans; Macaca fascicularis; Male; Oxazoles; Pharmacogenetics; Polymorphism, Single Nucleotide; PPAR gamma; Regression Analysis; Renin | 2008 |
Coadministration of muraglitazar plus glyburide: improvement of glycaemic and lipid profiles in patients with type 2 diabetes.
Topics: Administration, Oral; Adult; Aged; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glyburide; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Lipids; Male; Middle Aged; Oxazoles; PPAR alpha; PPAR gamma; Time Factors; Treatment Outcome | 2009 |
Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes.
Topics: Biomarkers; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Edema; Female; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Insulin; Lipids; Male; Middle Aged; Oxazoles; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones; Time Factors; Treatment Outcome; Weight Gain | 2009 |
Metabolic effects of muraglitazar in type 2 diabetic subjects.
Topics: Body Mass Index; Diabetes Mellitus, Type 2; Female; Glucose Clamp Technique; Glucose Tolerance Test; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Intra-Abdominal Fat; Male; Middle Aged; Oxazoles; Peroxisome Proliferator-Activated Receptors | 2011 |
The effect of muraglitazar on adiponectin signalling, mitochondrial function and fat oxidation genes in human skeletal muscle in vivo.
Topics: Adiponectin; AMP-Activated Protein Kinases; Biopsy; Blood Glucose; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glycine; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Mitochondria, Muscle; Muscle, Skeletal; Oxazoles; Oxidation-Reduction; PPAR alpha; PPAR gamma; Signal Transduction; Triglycerides | 2015 |
45 other study(ies) available for muraglitazar and glycine
| Article | Year |
|---|---|
Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and
Topics: Adipocytes; Animals; Blood Glucose; Cell Line; Diabetes Mellitus, Type 2; Fatty Acids; Glycine; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Mice; Mice, Obese; Oxazoles; PPAR alpha; PPAR gamma; Transcriptional Activation; Triglycerides | 2005 |
Molecule of the month. Muraglitazar.
Topics: Diabetes Mellitus, Type 2; Glycine; Humans; Oxazoles; PPAR alpha; PPAR gamma | 2005 |
American Diabetes Association - 65th Scientific Sessions. PPAR agents.
Topics: Alkanesulfonates; Animals; Blood Glucose; Diabetes Mellitus; Glycine; Humans; Hypoglycemic Agents; Oxazoles; Peroxisome Proliferator-Activated Receptors; Phenylpropionates | 2005 |
Meeting highlights. 65th annual scientific sessions of the American Diabetes Association, San Diego. Dual PPAR agonist improves glycemic control, lipids in type 2 diabetes.
Topics: Diabetes Mellitus, Type 2; Glycine; Humans; Hypoglycemic Agents; Metabolic Syndrome; Oxazoles; Pioglitazone; Thiazolidinediones; United States | 2005 |
Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.
Topics: Cardiovascular Diseases; Clinical Trials as Topic; Data Interpretation, Statistical; Diabetes Mellitus, Type 2; Drug Approval; Glycine; Humans; Hypoglycemic Agents; Oxazoles; PPAR alpha; PPAR gamma; Risk; Treatment Outcome; United States; United States Food and Drug Administration | 2005 |
Selling safety--lessons from muraglitazar.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Approval; Glycine; Humans; Hypoglycemic Agents; Oxazoles; PPAR alpha; PPAR gamma; Risk; United States; United States Food and Drug Administration | 2005 |
One pill, two conditions.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Glycine; Humans; Hypercholesterolemia; Oxazoles; United States | 2005 |
Paradoxical inflammation revisited: muraglitazar and cardiovascular risk.
Topics: Cardiovascular Diseases; Glycine; Humans; Hypoglycemic Agents; Oxazoles; Risk | 2006 |
Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.
Topics: Adiponectin; Animals; Blood Glucose; Corticosterone; Diabetes Mellitus, Type 2; Diet; Female; Glycine; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Liver; Mice; Obesity; Oxazoles; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Thiazolidinediones | 2006 |
Glucuronidation as a major metabolic clearance pathway of 14c-labeled muraglitazar in humans: metabolic profiles in subjects with or without bile collection.
Topics: Bile; Carbon Radioisotopes; Glucuronides; Glycine; Humans; Male; Metabolic Clearance Rate; Metabolic Detoxication, Phase II; Molecular Structure; Oxazoles; PPAR alpha; PPAR gamma | 2006 |
A 96-well single-pot protein precipitation, liquid chromatography/tandem mass spectrometry (LC/MS/MS) method for the determination of muraglitazar, a novel diabetes drug, in human plasma.
Topics: Animals; Chemical Precipitation; Chromatography, Liquid; Drug Stability; Glycine; Humans; Hypoglycemic Agents; Oxazoles; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2006 |
Biotransformation of carbon-14-labeled muraglitazar in male mice: interspecies difference in metabolic pathways leading to unique metabolites.
Topics: Animals; Bile; Bile Ducts; Biotransformation; Chromatography, High Pressure Liquid; Feces; Glutathione; Glycine; Haplorhini; Humans; Hypoglycemic Agents; Male; Mass Spectrometry; Mice; Oxazoles; Rats; Species Specificity; Spectrophotometry, Ultraviolet; Taurine | 2006 |
Liquid chromatography/mass spectrometry for the quantitation of muraglitazar in monkey plasma.
Topics: Animals; Chromatography, High Pressure Liquid; Glycine; Haplorhini; Mass Spectrometry; Oxazoles; Reproducibility of Results | 2006 |
A 96-well single-pot liquid-liquid extraction, hydrophilic interaction liquid chromatography-mass spectrometry method for the determination of muraglitazar in human plasma.
Topics: Chromatography, Liquid; Glycine; Humans; Oxazoles; PPAR alpha; PPAR gamma; Reference Standards; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2006 |
Drug safety system needs overhaul, experts say.
Topics: Cardiovascular Diseases; Conflict of Interest; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Glycine; Heart; Humans; Journalism, Medical; Oxazoles; Peroxisome Proliferator-Activated Receptors; Publication Bias; United States; United States Food and Drug Administration | 2006 |
Adverse events related to muraglitazar use in diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Interactions; Glycine; Humans; Hypoglycemic Agents; Oxazoles; Pioglitazone; PPAR alpha; PPAR gamma; Thiazolidinediones | 2006 |
Adverse events related to muraglitazar use in diabetes.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Interactions; Glycine; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Oxazoles; PPAR alpha; PPAR gamma | 2006 |
Muraglitazar: beneficial or detrimental in the treatment of Type 2 diabetes?
Topics: Adolescent; Adult; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glycine; Humans; Hypoglycemic Agents; Middle Aged; Oxazoles; Randomized Controlled Trials as Topic; Research Design; Weight Gain | 2006 |
Is it safe to combine PPAR agonists? A lesson from muraglitazar.
Topics: Cardiomyopathies; Drug Interactions; Glycine; Humans; Models, Biological; Oxazoles; PPAR alpha; PPAR gamma | 2006 |
Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase enzymes in the in vitro metabolism of muraglitazar.
Topics: Antibodies, Monoclonal; Biotransformation; Cells, Cultured; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Glucuronosyltransferase; Glycine; Hepatocytes; Humans; Microsomes, Liver; Oxazoles; Oxidation-Reduction; PPAR alpha; PPAR gamma | 2007 |
Assessment of dose proportionality of muraglitazar after repeated oral dosing in rats via a sparse sampling methodology.
Topics: Administration, Oral; Animals; Female; Glycine; Hypoglycemic Agents; Hypolipidemic Agents; Male; Oxazoles; PPAR alpha; PPAR gamma; Rats; Rats, Sprague-Dawley; Time Factors | 2007 |
Subchronic urinary bladder effects of muraglitazar in male rats.
Topics: Age Factors; Animals; Apoptosis; Calcium; Cell Proliferation; Citrates; Creatinine; Dose-Response Relationship, Drug; Epidermal Growth Factor; Female; Glycine; Hyperplasia; Magnesium; Male; Oxalates; Oxazoles; Peroxisome Proliferators; Phosphorus; PPAR alpha; PPAR gamma; Rats; Rats, Sprague-Dawley; Sex Factors; Time Factors; Urinary Bladder; Urine; Urothelium | 2007 |
Pharmacokinetics of muraglitazar (BMS-298585), a dual peroxisome proliferator-activated receptors (PPAR) alpha and gamma activator, in mice, rats, dogs, and monkeys.
Topics: Administration, Oral; Animals; Biological Availability; Cross-Over Studies; Dogs; Glycine; Half-Life; Hepatocytes; In Vitro Techniques; Injections, Intravenous; Macaca fascicularis; Male; Metabolic Clearance Rate; Mice; Mice, Inbred BALB C; Oxazoles; PPAR alpha; PPAR gamma; Rats; Rats, Sprague-Dawley; Species Specificity | 2006 |
Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: Evidence for urolithiasis as the inciting event in the mode of action.
Topics: Animals; Antimetabolites; Apoptosis; Area Under Curve; Bromodeoxyuridine; Calcium; Carcinogens; Cell Proliferation; Citrates; Electrolytes; Glycine; Hydrogen-Ion Concentration; Immunohistochemistry; Male; Microscopy, Electron, Scanning; Organ Size; Oxalates; Oxazoles; Phosphates; PPAR alpha; PPAR gamma; Proteinuria; Rats; Rats, Sprague-Dawley; Spectrometry, X-Ray Emission; Urinary Bladder Neoplasms; Urolithiasis; Urothelium | 2006 |
Increase in weight induced by muraglitazar, a dual PPARalpha/gamma agonist, in db/db mice: adipogenesis/or oedema?
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; Blood Glucose; Body Weight; Cell Differentiation; Edema; Epithelial Sodium Channels; Erythrocyte Count; Fatty Acids; Glycine; Hemoglobins; Kidney; Mice; Mice, Inbred Strains; Oxazoles; PPAR alpha; PPAR gamma; RNA, Messenger; Rosiglitazone; Sodium; Sodium-Potassium-Exchanging ATPase; Thiazolidinediones; Transcriptional Activation | 2007 |
The dual peroxisome proliferator-activated receptor alpha/gamma activator muraglitazar prevents the natural progression of diabetes in db/db mice.
Topics: Animals; Body Weight; C-Peptide; Diabetes Mellitus, Experimental; Disease Progression; Fatty Acids, Nonesterified; Female; Glucose Tolerance Test; Glycated Hemoglobin; Glycine; Hypoglycemic Agents; Insulin; Islets of Langerhans; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Oxazoles; Pancreas; PPAR alpha; PPAR gamma; Triglycerides | 2007 |
Rodent carcinogenicity profile of the antidiabetic dual PPAR alpha and gamma agonist muraglitazar.
Topics: Animals; Carcinogenicity Tests; Carcinogens; Dose-Response Relationship, Drug; Female; Glycine; Hypoglycemic Agents; Male; Mice; Mice, Inbred ICR; Neoplasms; Oxazoles; PPAR alpha; PPAR gamma; Rats; Rats, Sprague-Dawley; Survival Analysis; Urinalysis | 2007 |
Design, synthesis, and structure-activity relationship of carbamate-tethered aryl propanoic acids as novel PPARalpha/gamma dual agonists.
Topics: Carbamates; Chemistry, Pharmaceutical; Drug Design; Glycine; Models, Chemical; Models, Molecular; Molecular Structure; Oxazoles; PPAR alpha; PPAR gamma; Propionates; Rosiglitazone; Stereoisomerism; Structure-Activity Relationship; Thiazolidinediones; Transcriptional Activation | 2007 |
Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist.
Topics: Administration, Oral; Animals; Carcinogenicity Tests; Consumer Product Safety; Dogs; Female; Glycine; Hypoglycemic Agents; Lethal Dose 50; Macaca fascicularis; Male; Mice; Mice, Inbred ICR; Oxazoles; PPAR alpha; PPAR gamma; Promoter Regions, Genetic; Rabbits; Rats; Rats, Sprague-Dawley; Risk Assessment; Species Specificity; Toxicity Tests, Chronic; Transcriptional Activation | 2007 |
A bumpy road to breakthroughs. The news: it's hard to beat today's cardiac treatments.
Topics: Animals; Atherosclerosis; Coronary Thrombosis; Diabetes Mellitus, Type 2; Ethics, Clinical; Glycine; Heart Failure; Humans; Indoleacetic Acids; Myocardial Infarction; Oxazoles; Prostheses and Implants; Stroke; Treatment Failure; Ultrasonography | 2006 |
Accessing FDA approval packages and briefing documents.
Topics: Documentation; Drug Approval; Glycine; Ketolides; Oxazoles; United States; United States Food and Drug Administration | 2007 |
Optimization to eliminate the interference of migration isomers for measuring 1-O-beta-acyl glucuronide without extensive chromatographic separation.
Topics: Animals; Chromatography, High Pressure Liquid; Feasibility Studies; Glucuronides; Glycine; Haplorhini; Humans; Isomerism; Mice; Oxazoles; PPAR alpha; PPAR gamma; Rats | 2008 |
Therapy for nonalcoholic fatty liver disease.
Topics: Animals; Antioxidants; Cholagogues and Choleretics; Disease Models, Animal; Fatty Liver; Glycine; Humans; Hypolipidemic Agents; Insulin Resistance; Liver; Mice; Oxazoles; Peroxisome Proliferator-Activated Receptors; Rats; Thiazolidinediones; Treatment Outcome; Ursodeoxycholic Acid; Vitamin E | 2008 |
Modulation of PPAR receptor subtype selectivity of the ligands: aliphatic chain vs aromatic ring as a spacer between pharmacophore and the lipophilic moiety.
Topics: Butyrates; Chemistry, Pharmaceutical; Dioxanes; Drug Design; Glycine; Humans; Hydrogen; Hydrogen Bonding; Ligands; Models, Chemical; Oxazoles; Peroxisome Proliferator-Activated Receptors; PPAR alpha; Transcriptional Activation | 2008 |
Mass defect filtering on high resolution LC/MS data as a methodology for detecting metabolites with unpredictable structures: identification of oxazole-ring opened metabolites of muraglitazar.
Topics: Administration, Oral; Chromatography, High Pressure Liquid; Chromatography, Liquid; Feces; Glycine; Humans; Mass Spectrometry; Oxazoles; PPAR alpha; PPAR gamma | 2007 |
Rapid and sensitive characterization of the metabolite formation enzyme kinetics of radiolabeled drugs using stop-flow liquid radiochromatography.
Topics: Buspirone; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Glucuronides; Glycine; Humans; Indoles; Microsomes, Liver; Oxazoles; Reproducibility of Results; Scintillation Counting | 2008 |
PPAR-alpha and PPAR-gamma agonists for type 2 diabetes.
Topics: Alkanesulfonates; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Glycine; Humans; Hypoglycemic Agents; Oxazoles; Phenylpropionates; PPAR alpha; PPAR gamma; Thiophenes | 2009 |
Improving access to FDA reviews and documents.
Topics: Clinical Trials as Topic; Drug Approval; Glycine; Humans; Information Dissemination; Oxazoles; Peer Review, Research; Peroxisome Proliferator-Activated Receptors; Publication Bias; United States; United States Food and Drug Administration | 2009 |
Plasma stability-dependent circulation of acyl glucuronide metabolites in humans: how circulating metabolite profiles of muraglitazar and peliglitazar can lead to misleading risk assessment.
Topics: Adult; Animals; Bile; Drug Stability; Glucuronides; Glycine; Hepatocytes; Humans; Macaca fascicularis; Male; Mice; Microsomes, Liver; Oxazoles; Oxidation-Reduction; PPAR alpha; PPAR gamma; Rats; Risk Assessment; Uridine Diphosphate Glucuronic Acid; Young Adult | 2011 |
Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in rat hepatocytes.
Topics: Alkanesulfonates; Animals; Chromans; Gene Expression Profiling; Genes; Glycine; Hepatocytes; Humans; Male; Oligonucleotide Array Sequence Analysis; Oxazoles; Phenylpropionates; PPAR alpha; PPAR gamma; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones; Troglitazone | 2011 |
The development of subcutaneous sarcomas in rodents exposed to peroxisome proliferators agonists: hypothetical mechanisms of action and de-risking attitude.
Topics: Adipogenesis; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Cell Differentiation; Chromans; Diabetes Mellitus, Type 2; DNA Damage; Glycine; Hypoglycemic Agents; Ion Channels; Mice; Mitochondria; Mitochondrial Proteins; Oxazoles; Oxidative Stress; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Pioglitazone; PPAR alpha; PPAR gamma; Rats; RNA-Binding Proteins; Rodentia; Rosiglitazone; Sarcoma; Thermogenesis; Thiazolidinediones; Transcription Factors; Troglitazone; Uncoupling Protein 1 | 2012 |
Anti-inflammatory properties of a dual PPARgamma/alpha agonist muraglitazar in in vitro and in vivo models.
Topics: Animals; Anti-Inflammatory Agents; Blotting, Western; Enzyme-Linked Immunosorbent Assay; Gene Expression; Glycine; HEK293 Cells; Humans; In Vitro Techniques; Inflammation; Macrophages; Mice; Oxazoles; PPAR alpha; PPAR gamma; Real-Time Polymerase Chain Reaction | 2013 |
PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.
Topics: Cell Line; Constitutive Androstane Receptor; Drug Evaluation, Preclinical; Fatty Acids, Nonesterified; Fatty Liver; Gene Expression Regulation; Glycine; Humans; Lipid Metabolism; Lipogenesis; Lipotropic Agents; Liver; Liver X Receptors; Non-alcoholic Fatty Liver Disease; Oleic Acid; Orphan Nuclear Receptors; Oxazoles; Oxidation-Reduction; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Receptors, Cytoplasmic and Nuclear; Triglycerides | 2014 |
Muraglitazar-eluting bioabsorbable vascular stent inhibits neointimal hyperplasia in porcine iliac arteries.
Topics: Animals; Coated Materials, Biocompatible; Drug-Eluting Stents; Glycine; Hyperplasia; Iliac Artery; Oxazoles; Swine; Tunica Intima | 2015 |
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Glucose; Glycated Hemoglobin; Glycine; Government Regulation; Humans; Hypoglycemic Agents; Oxazoles; Phenylbutazone; Practice Guidelines as Topic; Risk; Rosiglitazone; Tolbutamide; United States; United States Food and Drug Administration | 2020 |